<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Melasma: Epidemiology, pathogenesis, clinical presentation, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pearl E Grimes, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3590020249"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Melasma is a common, chronic, and recurring disorder of hyperpigmentation arising from hyperfunctional melanocytes that deposit excessive amounts of melanin in the epidermis and dermis [<a href="#rid1">1</a>]. Melasma is particularly common in females (especially those of reproductive age) and in body areas with high amounts of sun exposure (notably the face) [<a href="#rid2">2-4</a>]. Contributing factors involved in the pathogenesis of this condition include genetic influences, sun exposure, sensitivity to hormones, pregnancy, and, in some cases, medications. The treatment of melasma is challenging, and relapses are universal. Patients must adhere to a rigorous therapeutic regimen to avoid relapses [<a href="#rid5">5,6</a>].</p><p>This topic will discuss the pathogenesis and clinical manifestations of melasma. The management of melasma is discussed separately. Other acquired disorders of hyperpigmentation are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p></p><p class="headingAnchor" id="H543795800"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Overall, the prevalence of melasma in the general population is approximately 1 percent, but it can be as high as 9 to 50 percent in high-risk populations [<a href="#rid7">7</a>]. Between 4 and 10 percent of people presenting to dermatology clinics in Central and South America may have melasma [<a href="#rid4">4</a>].</p><p>Melasma most frequently presents in females of reproductive age. The mean age of onset in two studies from Brazil was approximately 28 years [<a href="#rid8">8,9</a>]. The mean age of onset in 140 cases from India was 37 years [<a href="#rid10">10</a>]. A survey of 324 women being treated for melasma in nine countries reported a mean age of onset of 34 years [<a href="#rid11">11</a>]. The Fitzpatrick phototype of a patient may influence the age of onset. In a group of melasma patients from Brazil, the mean age of onset was 27 years in those with type II skin, 28 years in type III, 30 years in type IV, and 35 years in type V [<a href="#rid12">12</a>]. These results suggest that lighter skin may be a predisposing factor due to its susceptibility to photodamage.</p><p>The prevalence of melasma in males varies across studies. Studies from India report that 26 to 32 percent of patients with melasma are males [<a href="#rid10">10</a>]. In a Brazilian study of 953 adults with melasma, only 2.5 percent of the patients were males [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H398254236"><span class="h1">RISK AND TRIGGER FACTORS</span><span class="headingEndMark"> — </span>Genetic predisposition, exposure to sunlight (including ultraviolet [UV] and, possibly, visible light), skin phototype, and hormonal factors (including pregnancy, hormonal therapies, and use of oral contraceptives) are the main risk and trigger factors for melasma [<a href="#rid5">5,9,13</a>]. Additional factors associated with the development of melasma may include some cosmetics, certain medicines (eg, photosensitizing drugs and anticonvulsants), and zinc deficiency [<a href="#rid9">9,14,15</a>].</p><p>In a study of 324 women from nine countries, 90 percent of patients with a family history of melasma had Fitzpatrick phototypes III to IV compared with 77 percent of those without a family history [<a href="#rid11">11</a>]. This multinational study also supported suggestions that hormonal changes might contribute to the etiology of melasma. For example, 42 and 26 percent of cases occurred after or during pregnancy, respectively, with UV exposure being a contributing factor; each additional 10 hours a week that the person spent working outside increased the risk of melasma during pregnancy by approximately 27 percent. Maternal age at pregnancy increased the risk by approximately 8 percent for each year older at primigravida. The number of pregnancies increased the risk that melasma would first emerge during pregnancy, doubling and tripling for two and three or more pregnancies, compared with primigravida. Moreover, 25 percent of women who used oral contraception said that melasma appeared for the first time after they used the pill. The risk of melasma associated with the contraceptive pill was more than twofold higher in women with a family history of melasma compared with those without family history (odds ratio 2.45, 95% CI 1.10-5.46) [<a href="#rid11">11</a>].</p><p>A Brazilian study of 302 women with melasma reported that the most common triggers were pregnancy (36 percent), intense sun exposure (27 percent), and use of contraceptive pills (16 percent) [<a href="#rid9">9</a>]. Most patients were Fitzpatrick phototypes III (34 percent) and IV (38 percent). In another study of 953 Brazilian adults, UV exposure and pregnancy were identified as the most frequent triggers of melasma (in 44 and 24 percent of patients, respectively). This study also confirmed that melasma is most common in patients with Fitzpatrick III and IV phototypes (36 and 40 percent, respectively).</p><p>In another study, individuals with skin phototypes II and III and those with a family history of melasma had an earlier onset of melasma compared with those with skin phototypes IV, V, and VI; extrafacial melasma was more common in postmenopausal women than in premenopausal women (14 and 3.5 percent, respectively) [<a href="#rid12">12</a>].</p><p>Several studies suggest that melasma may be associated with abnormal thyroid function and thyroid autoimmunity [<a href="#rid9">9,16</a>]. A study of 45 women with melasma and 45 matched controls found increased levels in free thyroxine, thyroid-stimulating hormone (TSH), and thyroglobulin antibodies in women with melasma but not in controls [<a href="#rid16">16</a>]. Another study found a prevalence of increased TSH levels of 24 percent [<a href="#rid9">9</a>]. High levels of TSH were associated with UV-induced melasma (odds ratio 2.15, 95% CI 1.00-4.69). However, further studies are needed to elucidate the role of thyroid disorders in the pathogenesis of melasma.</p><p class="headingAnchor" id="H853998583"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H1280376543"><span class="h2">General features</span><span class="headingEndMark"> — </span>The epidermis of melasma lesions shows hyperactive melanocytes without hyperplasia [<a href="#rid2">2</a>]. Although the melanocyte number is similar in lesional and perilesional skin, melanocytes in the affected skin are larger, contain more and singly dispersed melanosomes, and show more and very prominent dendrites that can extend into the basal layer  (<a class="graphic graphic_picture graphicRef122973 graphicRef122093" href="/z/d/graphic/122973.html" rel="external">picture 1A-B</a>) [<a href="#rid1">1,17,18</a>]. In lesional skin, keratinocytes also show an increased number of melanosomes compared with healthy skin [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2595429206"><span class="h2">Disruption to the basement membrane</span><span class="headingEndMark"> — </span>The penetration of melanocytes and melanin into the dermis seems to be an important reason why melasma often proves difficult to treat and commonly relapses [<a href="#rid6">6</a>]. Estimates of the prevalence of disruption of the basement membrane in melasma lesions vary widely, depending on the experimental technique [<a href="#rid6">6</a>]. However, a study using sensitive methodologies reported that up to 83 to 96 percent of people with melasma show disruption of the basement membrane in their lesions [<a href="#rid19">19</a>]. Increased levels of matrix metalloproteinases (MMPs) 2 and 9, which degrade collagen, also appear to facilitate the movement of melanocytes into the dermis [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1964374461"><span class="h2">Lymphohistiocytic infiltrates</span><span class="headingEndMark"> — </span>In a study of 21 melasma patients, 75 percent of lesions showed mild lymphohistiocytic infiltrates [<a href="#rid1">1</a>]. The infiltrate was characterized by significant enrichment of inflammatory cells, including CD4<sup>+</sup> T cells, CD68<sup>+</sup> macrophages, and mast cells, and increased levels of the inflammatory cytokine interleukin 17 (IL-17) and the enzyme cyclooxygenase 2 (COX-2), which synthesizes proinflammatory prostaglandins from arachidonic acid, compared with unaffected skin [<a href="#rid3">3,6</a>].</p><p>In a histochemical and immunohistochemical study of biopsies from 20 women with malar melasma, levels of CD4<sup>+</sup> T cells and COX-2 expression were associated positively with the Melasma Activity and Severity Index (MASI) score. COX-2 expression was also associated positively with dermal elastosis and epidermal melanin deposition. The findings suggest that chronic inflammation may contribute to melasma, which may partly explain why recurrences are common [<a href="#rid3">3</a>]. Indeed, there seems to be an inflammatory phenotype of melasma [<a href="#rid20">20</a>]. These patients showed increased numbers of CD68<sup>+</sup> melanophages, leucocytes expressing the leucocyte common antigen, and CD117<sup>+</sup> mast cells than noninflammatory lesions [<a href="#rid20">20</a>].</p><p>Melasma lesions have shown increased mast cell infiltration compared with perilesional skin [<a href="#rid19">19</a>]. Mast cells contribute to dermal elastosis, disruption of the basement membrane, and vasodilation. Histamine released by mast cells seems to stimulate the proliferation and migration of melanocytes [<a href="#rid6">6</a>]. Further research needs to fully elucidate the role of mast cells in the pathogenesis of melasma.</p><p class="headingAnchor" id="H4188064485"><span class="h2">Dermal elastosis</span><span class="headingEndMark"> — </span>Melasma lesions show dermal elastosis, a hallmark of photoaging [<a href="#rid19">19,21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/15255.html" rel="external">"Photoaging"</a>.)</p><p>In a study of 56 Korean patients with melasma, the involved skin showed moderate to severe elastosis in 93 percent of cases, while normal skin exhibited elastosis in 70 percent [<a href="#rid21">21</a>]. Indeed, photoaging seems to have a central place in the pathogenesis of melasma, mediated by ultraviolet (UV) and visible light, release of melanogenic cytokines (eg, stem cell factor, endothelin 1, hepatocyte growth factor) from fibroblasts, and upregulation of the Wnt signaling pathway [<a href="#rid6">6,19</a>]. In addition, melasma lesions show increased expression of <em>c-kit</em>, the gene that encodes the stem cell factor receptor, compared with perilesional skin [<a href="#rid19">19</a>]. In a study of 50 Indian females, skin biopsies from melasma and perilesional normal skin revealed significant solar elastosis in the lesional skin compared with the perilesional skin [<a href="#rid22">22</a>]. Other changes included epidermal atrophy, basal cell hyperpigmentation, and pendulous melanocytes extending into the dermis.</p><p class="headingAnchor" id="H2592192063"><span class="h2">Increased vascularization</span><span class="headingEndMark"> — </span>Chronic UV exposure results in increased vascularization, and melasma lesions show greater numbers, size, and density of blood vessels in lesions compared with perilesional skin [<a href="#rid6">6,23</a>]. A study of 50 Korean women with melasma reported an increase in the number and size of dermal blood vessels in lesional skin compared with healthy skin [<a href="#rid23">23</a>]. The number of blood vessels correlated with the extent of hyperpigmentation. The expression of the proangiogenic vascular endothelial growth factor (VEGF) was significantly increased in lesions compared with healthy skin. VEGF also stimulates the release of arachidonic acid, which may affect melanogenesis. This observation dovetails with the increased expression of COX-2 in melasma lesions [<a href="#rid3">3</a>]. Indeed, melanocytes express VEGF receptors [<a href="#rid23">23</a>]. These results might support a role for antiangiogenic treatment in the management of melasma [<a href="#rid6">6</a>].</p><p>The signaling molecule nitric oxide mediates vascular tone as well as contributes to inflammation, skin immune function, and intracellular keratinocyte signaling [<a href="#rid24">24</a>]. UV radiation stimulates production of nitric oxide by upregulating expression of inducible nitric oxide synthase (iNOS) in keratinocytes. In turn, iNOS stimulates tyrosinase activity, which increases melanin synthesis. Lesions from nine melasma patients showed colocalization and a highly correlated association between iNOS protein and phosphorylated Akt (also called protein kinase B), part of an intracellular signaling pathway linked to the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells<strong> </strong>(NF-kB). The results suggest that melasma lesions show increased iNOS expression, probably mediated by activation of the Akt/NF-kB pathway [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3696479899"><span class="h2">Senescent fibroblasts</span><span class="headingEndMark"> — </span>Fibroblasts are essential for dermal integrity and pigmentation. They release stem cell factor and its epidermal receptor c-kit, transforming growth factor (TGF)-beta-1, and Dickkopf-related protein 1.</p><p>Senescent fibroblasts have been reported in lesional skin of patients with melasma. In a study of lesional and perilesional skin from 38 patients with melasma, using the senescence marker p16Ink4a, lesional skin demonstrated a significant increase in senescent fibroblasts. Fractional laser resurfacing therapy was shown to decrease the proportion of senescent fibroblasts in the aged dermis and improve pigmentation [<a href="#rid26">26,27</a>].</p><p>A study of cultured fibroblasts from melasma skin showed that fibroblasts were less fusiform in appearance and had a slowed growth rate, further supporting a senescent phenotype [<a href="#rid28">28</a>]. Such cells have the ability to secrete inflammatory cytokines, causing collagen degradation in the lesional skin of melasma. These findings support a photoaging phenotype.</p><p class="headingAnchor" id="H3401227548"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H2797321331"><span class="h2">Genetics and transcriptomic studies</span><span class="headingEndMark"> — </span>Melasma shows strong familial occurrence, especially in first-degree relatives [<a href="#rid8">8,9,11,12</a>], implicating a genetic basis for the hyperpigmentation. Nevertheless, relatively few genomic analyses (eg, genome-wide association studies) have identified genetic risk factors, although melasma is likely to show polygenic inheritance.</p><p>One study comparing 10 sample pairs of lesional and perilesional skin found differential expression of 279 genes in lesional and perilesional skin, with 187 genes upregulated and 152 genes downregulated in lesional skin [<a href="#rid17">17</a>]. Notably, expression of four genes associated with melanogenesis (<em>SILV</em>, <em>TYRP1</em>, <em>MLANA</em>, and <em>TYR</em>) and a subset of modulators of the Wnt pathway, which is critical for melanocyte development, were upregulated in lesional skin. Moreover, the gene encoding Wnt inhibitory factor 1 (<em>WIF-1</em>) was downregulated in melasma lesions compared with normally pigmented skin [<a href="#rid17">17</a>]. Further support for the involvement of Wnt signaling in melasma pathogenesis comes from a study of <em>WIF-1</em> knockdown fibroblasts and keratinocytes, which showed increased tyrosinase expression and melanosome transfer; in contrast, cells that overexpressed <em>WIF-1</em> attenuated these changes [<a href="#rid29">29</a>].</p><p>Increases in melanin biosynthesis underlie all hyperpigmentation diseases. However, while hyperpigmentation triggered by inflammation and ultraviolet (UV) light generally resolves spontaneously, melasma tends to be chronic and recurrent. One hypothesis to explain the different phenotypes focuses on the <em>H19</em> gene, which encodes a noncoding ribonucleic acid (RNA) that seems to control gene expression.</p><p class="headingAnchor" id="H279232531"><span class="h2">Ultraviolet and visible light</span><span class="headingEndMark"> — </span>Multiple studies suggest that ultraviolet (UV) light and visible light play a key role in the pathogenesis of melasma [<a href="#rid30">30-32</a>]. Melasma is most common in the tropics and areas with the highest UV radiation. The condition often improves during the winter months and with intense efforts to avoid exposure to UV radiation but relapses with exposure to UV radiation and visible light.</p><p class="bulletIndent1"><span class="glyph">●</span>UV radiation triggers a spectrum of events in the epidermis and dermis, including melanin synthesis; activation of tyrosinase, tyrosinase-related protein 1, and dopachrome tautomerase; and secretion of alpha-melanocyte-stimulating hormone (alpha-MSH), corticotrophin, and the ligand stem-cell factor [<a href="#rid33">33,34</a>]. UV radiation also triggers erythema, angiogenesis, and oxidative stress [<a href="#rid35">35</a>]. Studies document a role for visible light in triggering and sustaining melasma [<a href="#rid36">36</a>]. In a study evaluating the effectiveness of a broad-spectrum sunscreen in the prevention of melasma in 185 pregnant women, only 2.7 percent developed melasma when the anticipated rate was greater than 50 percent [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visible light activates the opsin 3 sensor receptor, triggering calcium-dependent microphthalmia transcription factor (MITF) signaling and the formation of <em>TYR</em>/dopachrome tautomerase protein complexes associated with long-lasting skin hyperpigmentation [<a href="#rid38">38</a>]. Investigations support the role of iron oxide's ability to mitigate hyperpigmentation induced by visible light [<a href="#rid39">39</a>]. Moreover, studies in melasma comparing the efficacy of photoprotection protocols incorporating iron oxide plus a broad-spectrum sunscreen with a broad-spectrum sunscreen alone showed superior outcomes in patients using the iron oxide and broad-spectrum photoprotection [<a href="#rid36">36,40</a>].</p><p></p><p class="headingAnchor" id="H3885046590"><span class="h2">Hormones</span><span class="headingEndMark"> — </span>Epidemiologic studies implicate hormones in the pathogenesis of melasma. (See <a class="local">'Risk and trigger factors'</a> above.) </p><p>For example, melasma is most common in females of reproductive age, and lesions often emerge following oral contraceptive use, pregnancy, menopause (for extrafacial involvement), or hormonal replacement therapy [<a href="#rid8">8-12</a>]. One study comparing gene and protein expression for estrogen receptor-beta (ER-beta) and progesterone receptor (PR) in facial melasma and adjacent healthy skin failed to find a difference in the expression of these genes in lesional skin compared with perilesional skin [<a href="#rid8">8</a>]. However, the epithelium of the lesions showed higher protein expression of these receptors, suggesting that female hormones contribute to the hyperpigmentation [<a href="#rid8">8</a>]. Estrogens stimulate melanogenesis by increasing the expression of alpha-MSH and inducing the synthesis of tyrosinase and tyrosinase-related proteins 1 and 2.</p><p>One study found that downregulation of <em>H19</em> in melasma skin induced tyrosinase overexpression and increased melanosome transfer [<a href="#rid41">41</a>]. Levels of <em>H19</em> RNA were at least twofold lower in melasma lesions than control skin. In cell culture, estrogens, but not UV irradiation, seemed to increase tyrosine overexpression mediated by <em>H19</em> RNA. However, this effect was apparent only in coculture of melanocytes and keratinocytes but not in melanocyte monoculture, underscoring the importance of intercellular signaling.</p><p>A study from Pakistan assessed blood levels of estrogen, progesterone, and prolactin in two consecutive follicular and luteal phases (day 9 and 18 of the menstrual cycle) in 138 women with melasma and 40 controls [<a href="#rid42">42</a>]. Only four melasma patients had normal values for all three hormones in all four phases. Nearly all patients (89 percent) had abnormal estrogen values (usually increased) in one or more of the four phases, whereas only 7.5 percent of controls had increased estrogen levels during both follicular and luteal phases. Fifty-five percent of melasma patients showed abnormal progesterone levels in all four phases; prolactin levels were normal in 97 percent.</p><p>Low testosterone levels have been observed in men with melasma [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H2555497945"><span class="h2">Barrier function and oxidative stress</span><span class="headingEndMark"> — </span>Chronic UV exposure reduces synthesis of epidermal free fatty acids and triglycerides, which are important in maintaining the skin's barrier function [<a href="#rid44">44</a>]. Studies suggest that skin from melasma lesions shows downregulation of several genes linked to lipid metabolism, a finding supported by the impaired barrier function characteristic of melasma [<a href="#rid17">17</a>]. A study of 16 melasma patients from Korea reported no difference in basal transepidermal water loss (TEWL), a marker of barrier function, or sebum content between lesions and healthy skin. However, after the barrier was disrupted by repeated tape stripping, TEWL was higher in lesional skin compared with healthy skin. The barrier function also took longer to recover in lesions. A trend suggesting thinner stratum corneum correlated with the rate at which barrier function recovered [<a href="#rid44">44</a>].</p><p>In the same study, the immunoreactivity of peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which regulates lipid catabolism, was lower in the lesions of 6 of 11 patients with melasma [<a href="#rid44">44</a>]. PPAR-gamma seems to modulate skin aging, melanogenesis, and antioxidant balance [<a href="#rid45">45</a>].</p><p>Oxidative stress may contribute to melasma. An Indian study reported significantly higher blood levels of the antioxidants malondialdehyde, superoxide dismutase, and glutathione in 50 patients with melasma compared with the same number of matched controls [<a href="#rid46">46</a>]. Levels of these antioxidants correlated positively with the Melasma Activity and Severity Index (MASI) score, reaching statistical significance with malondialdehyde. Increasing PPAR-gamma activity might offer a new approach to the management of photo-oxidative skin damage and melasma [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1958830781"><span class="h2">Neural involvement</span><span class="headingEndMark"> — </span>Melasma lesions often follow the path of the trigeminal nerves, which implies a neural component to the pathogenesis [<a href="#rid2">2</a>]. A study of six Korean women reported that melasma lesions showed increased expression of nerve growth factor receptor and neural endopeptidase compared with healthy skin. The authors suggest that nerve growth factor may modulate the microenvironment around melanocytes. The increased neural endopeptidase expression could influence melanogenesis. Therefore, an antagonist against these targets might offer a novel melasma therapy [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H374431423"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Melasma typically presents with irregular, light-brown to gray-brown macules and patches on sun-exposed skin [<a href="#rid2">2</a>]. The lesions are usually symmetric and may affect the forehead, nose, cheeks, upper lip area, and chin [<a href="#rid2">2</a>]. In most patients, melasma is asymptomatic. However, one study suggested that itching, tingling, dryness, erythema, or telangiectasia may herald inflammatory melasma, which is characterized by increased vascularization with telangiectasias and erythema [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Facial melasma</strong> – Common facial patterns of distribution for melasma include  (<a class="graphic graphic_figure graphicRef122094" href="/z/d/graphic/122094.html" rel="external">figure 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Centrofacial pattern</strong> – Centrofacial melasma commonly affects the forehead, cheeks, nose, upper lip, and chin areas  (<a class="graphic graphic_picture graphicRef122098 graphicRef75884 graphicRef64109 graphicRef52220" href="/z/d/graphic/122098.html" rel="external">picture 2A-D</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malar pattern</strong> – Malar melasma predominately involves the lateral cheek areas  (<a class="graphic graphic_picture graphicRef122095" href="/z/d/graphic/122095.html" rel="external">picture 2E</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mandibular pattern</strong> – Mandibular melasma affects the lower jawline  (<a class="graphic graphic_picture graphicRef122097" href="/z/d/graphic/122097.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1">In a Brazilian study of 302 women with melasma, most patients had at least six facial regions affected, most commonly the zygomatic (84 percent), labial superior (51 percent), and frontal (50 percent) regions [<a href="#rid9">9</a>]. Another Brazilian study reported that melasma first appeared in the malar region in 70 percent of patients. Overall, the malar (90 percent), frontal (53 percent), upper lips (52 percent), and nose (34 percent) were the most commonly affected areas [<a href="#rid12">12</a>]. A study from India also found that the malar was the most common region affected (68 percent), followed by the central face (25 percent) and mandible (7 percent) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extrafacial melasma</strong> – Some patients, predominantly females, develop extrafacial melasma, which is less common than the facial phenotype and is usually difficult to treat  (<a class="graphic graphic_picture graphicRef89286" href="/z/d/graphic/89286.html" rel="external">picture 4</a>). Extrafacial melasma tends to emerge at an older age than the facial form and may be associated with menopause. In one study, 81 percent of women with extrafacial melasma had reached menopause, and the mean age at presentation was 56.7 years [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">In one study, approximately 8 percent of patients with facial involvement showed extrafacial occurrence [<a href="#rid9">9</a>]. In a study of 45 patients with extrafacial melasma, the sites of involvement were the arms (95 percent), forearms (80 percent), chest (47 percent), or back (11 percent) [<a href="#rid47">47</a>]. The lesions, which were present for more than five years in approximately one-half of the patients, tended to show moderate intensity and homogeneity [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H4152692329"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>Melasma is a chronic and recurrent condition. Although spontaneous remission may occur after pregnancy, pregnancy-related melasma can persist for several months after birth or indefinitely [<a href="#rid4">4</a>]. Independently from the trigger event for melasma, relapses occur with mild to intense sun exposure. While spontaneous remission may occur after pregnancy, such patients may have subsequent flares of the melasma.</p><p>In one study of 245 women with melasma who had had at least one pregnancy, 15 (6 percent) experienced spontaneous remission after each pregnancy [<a href="#rid11">11</a>]. Of note, spontaneous remission occurred more frequently among women whose melasma first appeared during a pregnancy than in those whose melasma started at some other time (16 versus 2 percent).</p><p>Melasma associated with hormonal therapies can remain after treatment ceases. Melasma with an inflammatory component may be associated with a worse outcome using conventional treatments compared with melasma without a marked inflammatory component. A Korean study found that approximately 25 percent of 197 patients might have had the inflammatory subtype [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1183627184"><span class="h1">IMPACT ON QUALITY OF LIFE</span><span class="headingEndMark"> — </span>Multiple studies have documented the detrimental and psychologically devastating effects of melasma on quality of life. Emerging data suggest that melasma represents a photoaging skin disorder [<a href="#rid10">10,48,49</a>]. A seminal study reported that 65 percent of patients with melasma were dissatisfied by their hyperpigmentation all or most of the time [<a href="#rid48">48</a>]. Moreover, 57 percent of patients reported embarrassment, 55 percent experienced frustration, and 42 percent said that melasma affected interpersonal relationships. A study of 140 individuals with melasma from India found that 75 percent were bothered or frustrated by the disease most or all of the time [<a href="#rid10">10</a>]. Many of these patients reported that melasma was associated with depression (72 percent), embarrassment (71 percent), and negative appearance (42 percent) and had a negative impact on relationships with other people (42 percent) most or all of the time. In a systematic review and meta-analysis of 14 studies that included 1398 patients, melasma caused significant emotional distress and had a negative impact on patients' social lives [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H2377806598"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Melasma is generally diagnosed based on the clinical presentation and classified as epidermal, dermal, or mixed, depending on the location of melanin [<a href="#rid4">4</a>]. However, in most cases, there is pigment deposition in the epidermis and dermis. Elements of history that support the diagnosis include onset in relation to pregnancy or use of oral contraceptives, family history of melasma, and exposure to phototoxic drugs.</p><p>Wood's lamp examination may assist in identifying the location of pigment, especially in individuals with lighter complexions (Fitzpatrick phototypes I to III) [<a href="#rid4">4,51</a>]. Epidermal melanosis often manifests as well-circumscribed pigmentation with accentuated borders. In contrast, dermal melanosis typically appears poorly circumscribed and is not accentuated under Wood's lamp illumination. Wood's lamp examination is less reliable in Fitzpatrick phototypes IV, V, and VI. In these patients, the density of melanin can make variations between the skin layers difficult to differentiate [<a href="#rid4">4,51</a>].</p><p>Dermoscopy has become increasingly popular as an aid for diagnosing melasma and identifying the levels of pigment deposition. Dermoscopy can reveal accentuation of the normal pseudoreticular pigmentary network, increased vascularity, telangiectasia, pigment structures, and owl's eye structures [<a href="#rid52">52</a>]. Moreover, dermoscopy may be helpful to assess melasma severity, based on the pattern and density of pigmented structures [<a href="#rid52">52</a>].</p><p>The existence of true dermal melasma remains controversial. It is to be distinguished from Hori's nevus, a dermal melanocytosis commonly observed in Asian individuals. (See <a class="local">'Differential diagnosis'</a> below.) </p><p class="headingAnchor" id="H4075599189"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of melasma encompasses a wide range of disorders characterized by facial hyperpigmentation, including [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hori's nevus</strong> – Nevus of Hori is a common, acquired, dermal melanocytosis seen in Asian populations, primarily in young and middle-aged Chinese and Japanese females [<a href="#rid53">53</a>]. It presents as multiple speckled, blue-brown or slate-gray macules occurring bilaterally on the malar regions. Hori's nevus is recalcitrant to topical agents used to treat melasma. (See  <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders", section on 'Nevus of Hori'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Riehl's melanosis</strong> – Riehl's melanosis, also called pigmented contact dermatitis, is a dermal melanosis involving the face and neck caused, in most cases, by chemicals in cosmetics  (<a class="graphic graphic_picture graphicRef89290" href="/z/d/graphic/89290.html" rel="external">picture 5</a>) [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders", section on 'Riehl's melanosis (pigmented contact dermatitis)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema dyschromicum perstans</strong> – Erythema dyschromicum perstans is an uncommon, slowly progressive dermatosis characterized by hyperpigmented macules of variable size and shape of an ashen-gray color  (<a class="graphic graphic_picture graphicRef122117" href="/z/d/graphic/122117.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef122119" href="/z/d/graphic/122119.html" rel="external">picture 7</a>). (See  <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen planus pigmentosus</strong> – Lichen planus pigmentosus is a rare form of lichen planus that presents with oval or irregular, brown to gray-brown macules and patches most often located on sun-exposed areas of the skin, such as the face, or flexural areas. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus", section on 'Cutaneous variants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed drug eruptions</strong> – Fixed drug eruption is a cutaneous drug reaction that characteristically recurs in the same locations upon re-exposure to the offending drug. It typically presents with solitary, round to oval, dusky red to brown/black macules  (<a class="graphic graphic_picture graphicRef122129" href="/z/d/graphic/122129.html" rel="external">picture 8</a>). (See  <a class="medical medical_review" href="/z/d/html/15760.html" rel="external">"Fixed drug eruption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discoid lupus erythematosus</strong> – Discoid lupus erythematosus lesions of the face may present with postinflammatory hyperpigmentation as well as violaceous hyperpigmentation. However, hyperpigmented lesions are often interspersed with hypopigmented, scar-like areas  (<a class="graphic graphic_picture graphicRef122120" href="/z/d/graphic/122120.html" rel="external">picture 9</a>). (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Discoid lupus erythematosus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phototoxic dermatitis</strong> – Phototoxic reactions may occur to a number of systemic drugs, including tetracyclines, thiazide diuretics, fluoroquinolones, and nonsteroidal anti-inflammatory drugs. It usually presents as an exaggerated sunburn limited to the sun-exposed areas that may be followed by postinflammatory hyperpigmentation. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> may cause a slate-gray pigmentation in a photodistribution of the face  (<a class="graphic graphic_picture graphicRef70419" href="/z/d/graphic/70419.html" rel="external">picture 10</a>). (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phytophotodermatitis</strong> – Phytophotodermatitis is a cutaneous, phototoxic eruption caused by the contact with plant-derived substances, such as lemons or limes. It may present with hyperpigmented macules or patches with a bizarre shape corresponding to the areas of contact with the sensitizing substance. (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postinflammatory hyperpigmentation</strong> – Postinflammatory hyperpigmentation manifests as hyperpigmented macules or patches on the skin that match the distribution of the preceding inflammatory dermatosis or injury  (<a class="graphic graphic_picture graphicRef58817" href="/z/d/graphic/58817.html" rel="external">picture 11</a>). (See  <a class="medical medical_review" href="/z/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lentigines</strong> – Solar lentigines present with multiple tan to dark brown macules, often with irregular borders  (<a class="graphic graphic_picture graphicRef81287" href="/z/d/graphic/81287.html" rel="external">picture 12</a>). They typically occur in older adults on areas that are chronically exposed to the sun (eg, the face, dorsal hands, extensor forearms, and upper trunk). (See  <a class="medical medical_review" href="/z/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders", section on 'Solar lentigines'</a>.)</p><p></p><p>Additionally, clinicians should exclude exogenous ochronosis due to chronic topical treatment with, for example, <a class="drug drug_general" data-topicid="8539" href="/z/d/drug information/8539.html" rel="external">hydroquinone</a> [<a href="#rid55">55</a>]. It manifests as a localized, symmetric, blue-gray discoloration of the skin, with characteristic hyperchromic, pinpoint, caviar-like papules in photo-exposed regions. (See  <a class="medical medical_review" href="/z/d/html/110148.html" rel="external">"Topical skin-lightening agents: Complications of use in the nonmedical setting", section on 'Exogenous ochronosis'</a>.)</p><p class="headingAnchor" id="H3520328069"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/129725.html" rel="external">"Society guideline links: Melasma and hyperpigmentation disorders"</a>.)</p><p class="headingAnchor" id="H260113078"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Melasma is a chronic, therapeutically challenging, and universally relapsing condition that arises from hyperfunctional melanocytes that deposit excessive amounts of melanin in the epidermis and dermis. It typically occurs in females of reproductive age but may also be seen in males. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Genetic predisposition, exposure to sunlight (including ultraviolet [UV] and, possibly, visible light), skin phototype, and hormonal factors (including pregnancy, hormonal therapies, and oral contraceptives) are the main risk and trigger factors for melasma. (See <a class="local">'Risk and trigger factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Melasma typically presents as light brown to gray-brown macules and patches on sun-exposed skin. Lesions are usually symmetric and may affect the forehead, nose, cheeks, upper lip area, and chin  (<a class="graphic graphic_picture graphicRef122097" href="/z/d/graphic/122097.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef122098 graphicRef122095" href="/z/d/graphic/122098.html" rel="external">picture 2A, 2E</a>). Less commonly, melasma may occur on extrafacial sites, such as the forearms, chest, and back  (<a class="graphic graphic_picture graphicRef89286" href="/z/d/graphic/89286.html" rel="external">picture 4</a>). Melasma has a chronic and recurrent course. Relapsing occurs with mild to intense sun exposure even after successful treatment. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Clinical course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Melasma is generally diagnosed based on the clinical presentation. Wood's lamp examination may assist in identifying the location of pigment (epidermal or dermal), especially in individuals with lighter complexions (Fitzpatrick phototypes I to III). Dermoscopy is increasingly used as an aid for diagnosing melasma and identifying the level of pigment deposition. (See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol 2005; 27:96.</a></li><li><a class="nounderline abstract_t">Bak H, Lee HJ, Chang SE, et al. Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma. Dermatol Surg 2009; 35:1244.</a></li><li><a class="nounderline abstract_t">Rodríguez-Arámbula A, Torres-Álvarez B, Cortés-García D, et al. CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma. Am J Dermatopathol 2015; 37:761.</a></li><li><a class="nounderline abstract_t">Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev 2010; :CD003583.</a></li><li><a class="nounderline abstract_t">Passeron T. Melasma pathogenesis and influencing factors - an overview of the latest research. J Eur Acad Dermatol Venereol 2013; 27 Suppl 1:5.</a></li><li><a class="nounderline abstract_t">Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous Pathology of Melasma and Its Clinical Implications. Int J Mol Sci 2016; 17.</a></li><li><a class="nounderline abstract_t">Ogbechie-Godec OA, Elbuluk N. Melasma: an Up-to-Date Comprehensive Review. Dermatol Ther (Heidelb) 2017; 7:305.</a></li><li><a class="nounderline abstract_t">Tamega Ade A, Miot HA, Moço NP, et al. Gene and protein expression of oestrogen-β and progesterone receptors in facial melasma and adjacent healthy skin in women. Int J Cosmet Sci 2015; 37:222.</a></li><li><a class="nounderline abstract_t">Tamega Ade A, Miot LD, Bonfietti C, et al. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol 2013; 27:151.</a></li><li><a class="nounderline abstract_t">Yalamanchili R, Shastry V, Betkerur J. Clinico-epidemiological Study and Quality of Life Assessment in Melasma. Indian J Dermatol 2015; 60:519.</a></li><li><a class="nounderline abstract_t">Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol 2009; 23:1254.</a></li><li><a class="nounderline abstract_t">Hexsel D, Lacerda DA, Cavalcante AS, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol 2014; 53:440.</a></li><li><a class="nounderline abstract_t">Espósito ACC, Cassiano DP, da Silva CN, et al. Update on Melasma-Part I: Pathogenesis. Dermatol Ther (Heidelb) 2022; 12:1967.</a></li><li><a class="nounderline abstract_t">Rostami Mogaddam M, Safavi Ardabili N, Iranparvar Alamdari M, et al. Evaluation of the serum zinc level in adult patients with melasma: Is there a relationship with serum zinc deficiency and melasma? J Cosmet Dermatol 2018; 17:417.</a></li><li><a class="nounderline abstract_t">Duarte I, Campos Lage AC. Frequency of dermatoses associated with cosmetics. Contact Dermatitis 2007; 56:211.</a></li><li><a class="nounderline abstract_t">Çakmak SK, Özcan N, Kılıç A, et al. Etiopathogenetic factors, thyroid functions and thyroid autoimmunity in melasma patients. Postepy Dermatol Alergol 2015; 32:327.</a></li><li><a class="nounderline abstract_t">Kang HY, Suzuki I, Lee DJ, et al. Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma. J Invest Dermatol 2011; 131:1692.</a></li><li><a class="nounderline abstract_t">Funasaka Y, Mayumi N, Asayama S, et al. In vivo reflectance confocal microscopy for skin imaging in melasma. J Nippon Med Sch 2013; 80:172.</a></li><li><a class="nounderline abstract_t">Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, et al. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol 2011; 33:291.</a></li><li><a class="nounderline abstract_t">Noh TK, Choi SJ, Chung BY, et al. Inflammatory features of melasma lesions in Asian skin. J Dermatol 2014; 41:788.</a></li><li><a class="nounderline abstract_t">Kang WH, Yoon KH, Lee ES, et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146:228.</a></li><li><a class="nounderline abstract_t">Gautam M, Patil S, Nadkarni N, et al. Histopathological comparison of lesional and perilesional skin in melasma: A cross-sectional analysis. Indian J Dermatol Venereol Leprol 2019; 85:367.</a></li><li><a class="nounderline abstract_t">Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci 2007; 46:111.</a></li><li><a class="nounderline abstract_t">E Y, Golden SC, Shalita AR, et al. Neuropeptide (calcitonin gene-related peptide) induction of nitric oxide in human keratinocytes in vitro. J Invest Dermatol 2006; 126:1994.</a></li><li><a class="nounderline abstract_t">Jo HY, Kim CK, Suh IB, et al. Co-localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma. J Dermatol 2009; 36:10.</a></li><li><a class="nounderline abstract_t">Kim M, Kim SM, Kwon S, et al. Senescent fibroblasts in melasma pathophysiology. Exp Dermatol 2019; 28:719.</a></li><li><a class="nounderline abstract_t">Kim NH, Choi SH, Lee TR, et al. Cadherin 11 Involved in Basement Membrane Damage and Dermal Changes in Melasma. Acta Derm Venereol 2016; 96:635.</a></li><li><a class="nounderline abstract_t">Espósito ACC, Brianezi G, Miot LDB, Miot HA. Fibroblast morphology, growth rate and gene expression in facial melasma. An Bras Dermatol 2022; 97:575.</a></li><li><a class="nounderline abstract_t">Kim JY, Lee TR, Lee AY. Reduced WIF-1 expression stimulates skin hyperpigmentation in patients with melasma. J Invest Dermatol 2013; 133:191.</a></li><li><a class="nounderline abstract_t">Fatima S, Braunberger T, Mohammad TF, et al. The Role of Sunscreen in Melasma and Postinflammatory Hyperpigmentation. Indian J Dermatol 2020; 65:5.</a></li><li><a class="nounderline abstract_t">Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol 2010; 22:373.</a></li><li><a class="nounderline abstract_t">Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res 2018; 31:461.</a></li><li><a class="nounderline abstract_t">Kim TJ, Cho MK, Lee JS, et al. The expression of melanogenic proteins in Korean skin after ultraviolet irradiation. J Dermatol 2003; 30:665.</a></li><li><a class="nounderline abstract_t">Yardman-Frank JM, Fisher DE. Skin pigmentation and its control: From ultraviolet radiation to stem cells. Exp Dermatol 2021; 30:560.</a></li><li><a class="nounderline abstract_t">Sklar LR, Almutawa F, Lim HW, Hamzavi I. Effects of ultraviolet radiation, visible light, and infrared radiation on erythema and pigmentation: a review. Photochem Photobiol Sci 2013; 12:54.</a></li><li><a class="nounderline abstract_t">Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed 2014; 30:35.</a></li><li><a class="nounderline abstract_t">Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol 2007; 21:738.</a></li><li><a class="nounderline abstract_t">Regazzetti C, Sormani L, Debayle D, et al. Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3. J Invest Dermatol 2018; 138:171.</a></li><li><a class="nounderline abstract_t">Mohammad TF, Kohli I, Nicholson CL, et al. Oral Polypodium Leucotomos Extract and Its Impact on Visible Light-Induced Pigmentation in Human Subjects. J Drugs Dermatol 2019; 18:1198.</a></li><li><a class="nounderline abstract_t">Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol 2015; 72:189.</a></li><li><a class="nounderline abstract_t">Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res 2010; 23:84.</a></li><li><a class="nounderline abstract_t">Mahmood K, Nadeem M, Aman S, et al. Role of estrogen, progesterone and prolactin in the etiopathogenesis of melasma in females. J Pak Assoc Dermatol 2011; 21:241.</a></li><li><a class="nounderline abstract_t">Nukana RP, Rusyati LMM, Praharsini GAA, et al. Association of testosterone level with melasma in men: a case-control study in Indonesia. Pan Afr Med J 2022; 43:194.</a></li><li><a class="nounderline abstract_t">Lee DJ, Lee J, Ha J, et al. Defective barrier function in melasma skin. J Eur Acad Dermatol Venereol 2012; 26:1533.</a></li><li><a class="nounderline abstract_t">Briganti S, Flori E, Bellei B, Picardo M. Modulation of PPARγ provides new insights in a stress induced premature senescence model. PLoS One 2014; 9:e104045.</a></li><li><a class="nounderline abstract_t">Choubey V, Sarkar R, Garg V, et al. Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients. Int J Dermatol 2017; 56:939.</a></li><li><a class="nounderline abstract_t">Ritter CG, Fiss DV, Borges da Costa JA, et al. Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study. J Eur Acad Dermatol Venereol 2013; 27:1088.</a></li><li><a class="nounderline abstract_t">Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149:572.</a></li><li><a class="nounderline abstract_t">Platsidaki E, Efstathiou V, Markantoni V, et al. Self-Esteem, Depression, Anxiety and Quality of Life in Patients with Melasma Living in a Sunny Mediterranean Area: Results from a Prospective Cross-Sectional Study. Dermatol Ther (Heidelb) 2023; 13:1127.</a></li><li><a class="nounderline abstract_t">Zhu Y, Zeng X, Ying J, et al. Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis. PLoS One 2022; 17:e0262833.</a></li><li><a class="nounderline abstract_t">Shankar K, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb) 2014; 4:165.</a></li><li><a class="nounderline abstract_t">Vinay K, Bishnoi A, Parsad D, et al. Dermatoscopic evaluation and histopathological correlation of acquired dermal macular hyperpigmentation. Int J Dermatol 2017; 56:1395.</a></li><li><a class="nounderline abstract_t">Park JM, Tsao H, Tsao S. Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations. J Am Acad Dermatol 2009; 61:88.</a></li><li><a class="nounderline abstract_t">Kumarasinghe SPW, Pandya A, Chandran V, et al. A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol 2019; 58:263.</a></li><li><a class="nounderline abstract_t">Córdova ME, Pérez-Rojas DO, López-Marquet AD, Arenas R. Exogenous Ochronosis in Facial Melasma. Actas Dermosifiliogr 2017; 108:381.</a></li></ol></div><div id="topicVersionRevision">Topic 121155 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15798432" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438666" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Increased expression of nerve growth factor receptor and neural endopeptidase in the lesional skin of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26381025" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20614435" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interventions for melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205539" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Melasma pathogenesis and influencing factors - an overview of the latest research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240341" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heterogeneous Pathology of Melasma and Its Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28726212" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Melasma: an Up-to-Date Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439299" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gene and protein expression of oestrogen-βand progesterone receptors in facial melasma and adjacent healthy skin in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22212073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538717" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinico-epidemiological Study and Quality of Life Assessment in Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486232" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23967822" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiology of melasma in Brazilian patients: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35904706" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Update on Melasma-Part I: Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29131489" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evaluation of the serum zinc level in adult patients with melasma: Is there a relationship with serum zinc deficiency and melasma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17343621" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Frequency of dermatoses associated with cosmetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759539" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Etiopathogenetic factors, thyroid functions and thyroid autoimmunity in melasma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21562572" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23832400" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : In vivo reflectance confocal microscopy for skin imaging in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317614" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132344" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inflammatory features of melasma lesions in Asian skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903232" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Melasma: histopathological characteristics in 56 Korean patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30516167" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Histopathological comparison of lesional and perilesional skin in melasma: A cross-sectional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363223" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The vascular characteristics of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710309" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuropeptide (calcitonin gene-related peptide) induction of nitric oxide in human keratinocytes in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207431" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Co-localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575141" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Senescent fibroblasts in melasma pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671310" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cadherin 11 Involved in Basement Membrane Damage and Dermal Changes in Melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35840442" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fibroblast morphology, growth rate and gene expression in facial melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951732" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reduced WIF-1 expression stimulates skin hyperpigmentation in patients with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32029932" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Role of Sunscreen in Melasma and Postinflammatory Hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21165205" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : What should be considered in treatment of melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29285880" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Melasma, a photoaging disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578556" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The expression of melanogenic proteins in Korean skin after ultraviolet irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33320376" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Skin pigmentation and its control: From ultraviolet radiation to stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111621" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of ultraviolet radiation, visible light, and infrared radiation on erythema and pigmentation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313385" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17567299" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28842328" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Melanocytes Sense Blue Light and Regulate Pigmentation through Opsin-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31859468" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Oral Polypodium Leucotomos Extract and Its Impact on Visible Light-Induced Pigmentation in Human Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443629" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19968822" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : H19 RNA downregulation stimulated melanogenesis in melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of estrogen, progesterone and prolactin in the etiopathogenesis of melasma in females</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36942149" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of testosterone level with melasma in men: a case-control study in Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077137" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Defective barrier function in melasma skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101957" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Modulation of PPARγprovides new insights in a stress induced premature senescence model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28681382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Role of oxidative stress in melasma: a prospective study on serum and blood markers of oxidative stress in melasma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827850" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Extra-facial melasma: clinical, histopathological, and immunohistochemical case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510991" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Development and validation of a health-related quality of life instrument for women with melasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36995579" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Self-Esteem, Depression, Anxiety and Quality of Life in Patients with Melasma Living in a Sunny Mediterranean Area: Results from a Prospective Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085327" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25269451" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evidence-based treatment for melasma: expert opinion and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28971471" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dermatoscopic evaluation and histopathological correlation of acquired dermal macular hyperpigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539841" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acquired bilateral nevus of Ota-like macules (Hori nevus): etiologic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30176055" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A global consensus statement on ashy dermatosis, erythema dyschromicum perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126186" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Exogenous Ochronosis in Facial Melasma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
